Database Query Results : Iron, Magnetic Fields,

Fe, Iron: Click to Expand ⟱
Features:
Iron plays a dual and highly context-dependent role in cancer biology. It is essential for tumor proliferation due to its requirement in DNA synthesis (ribonucleotide reductase), mitochondrial respiration, and cell cycle progression. Many cancers exhibit increased iron uptake (↑ transferrin receptor, TfR1) and decreased iron export (↓ ferroportin), leading to intracellular iron accumulation that supports rapid growth. However, excess labile iron also promotes oxidative stress through Fenton chemistry (Fe²⁺ + H₂O₂ → •OH), contributing to DNA damage and genomic instability.

A major therapeutic concept is ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation. Tumors with high iron dependency can be selectively vulnerable to ferroptosis induction. Conversely, chronic iron overload may promote tumor initiation through ROS-mediated mutagenesis and inflammatory signaling.
Thus, iron sits at a metabolic intersection:
-Pro-tumor when supporting proliferation and ROS-driven mutation
-Anti-tumor when leveraged to trigger ferroptotic cell death

Iron biology in cancer is best understood through three axes:
-Iron uptake/storage/export balance
-ROS and oxidative stress dynamics
-Ferroptosis susceptibility
Iron is a vital trace element that plays essential roles in various physiological processes. Its importance stems from its involvement in oxygen transport, energy production, DNA synthesis, and numerous enzymatic reactions.
– Iron is a critical component of hemoglobin in red blood cells, enabling the binding and transport of oxygen from the lungs to tissues.
– Iron participates in redox reactions due to its ability to alternate between ferrous (Fe²⁺) and ferric (Fe³⁺) states.

Tumor cells often require increased iron to support their rapid proliferation and metabolic demands. – Elevated iron availability can promote DNA synthesis, cell division, and tumor growth.

• Promotion of Reactive Oxygen Species (ROS) Formation:
– Iron’s redox-active nature, while important for normal cell functions, can also lead to the generation of reactive oxygen species via reactions such as the Fenton reaction:
Fe²⁺ + H₂O₂ → Fe³⁺ + •OH + OH⁻
– The hydroxyl radicals (•OH) produced are highly reactive and can cause oxidative damage to cellular components (DNA, proteins, lipids).
– This oxidative damage may contribute to genomic instability, mutations, and the progression of cancer.

Cancer cells often exhibit increased iron dependency, targeting iron metabolism is a strategy that is being explored for cancer therapy.
– Approaches include the use of iron chelators to sequester iron and limit its availability to tumor cells, thereby inhibiting their growth.
– Alternatively, therapies may aim to exploit iron’s capacity to generate toxic ROS beyond a threshold that cancer cells can manage, leading to selective cell death.

Iron (Fe) – Cancer Pathway Matrix

Rank Pathway / Axis Cancer Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 Iron Uptake (TfR1 ↑) Transferrin receptor ↑; iron import ↑; supports rapid proliferation Regulated iron homeostasis G Pro-growth metabolic support Many tumors upregulate TfR1 to fuel DNA synthesis and mitochondrial metabolism.
2 Ribonucleotide Reductase DNA synthesis ↑; cell cycle progression ↑ Required for normal division R, G Proliferation driver Iron is a required cofactor for ribonucleotide reductase.
3 Fenton Chemistry → ROS ROS ↑; DNA damage ↑; genomic instability ↑ Oxidative injury risk if overload R, G Mutagenic driver Fe²⁺ catalyzes hydroxyl radical formation; promotes tumor initiation and progression.
4 Ferroptosis (iron-dependent lipid peroxidation) Lipid ROS ↑; ferroptotic death if GPX4 overwhelmed Normally suppressed by antioxidant systems R, G Therapeutic vulnerability High iron tumors may be selectively sensitive to ferroptosis induction.
5 Ferritin Storage Ferritin ↑ in many cancers; buffers labile iron pool Physiologic iron storage G Iron buffering / adaptation High ferritin can protect tumor cells from oxidative death.
6 Ferroportin (Export) ↓ Iron retention ↑; tumor growth support Maintains systemic balance G Pro-growth adaptation Reduced iron export correlates with aggressive phenotypes in some cancers.
7 NRF2 Axis NRF2 ↑ may increase ferritin and antioxidant defenses Protective oxidative stress response G Adaptive survival pathway NRF2 activation can protect against iron-driven oxidative stress and ferroptosis.
8 Inflammation (IL-6 / Hepcidin) Iron sequestration altered; tumor microenvironment modulation Systemic iron regulation G Microenvironmental modifier Inflammatory cytokines alter iron distribution and availability.
9 Anemia / Iron Depletion Hypoxia signaling ↑ (HIF-1α); therapy resistance context Fatigue, impaired oxygen delivery G Clinical constraint Iron deficiency anemia may worsen hypoxia-driven tumor aggressiveness.

Time-Scale Flag (TSF):
P = 0–30 min (redox reactions)
R = 30 min–3 hr (ROS signaling shifts)
G = >3 hr (proliferation, ferroptosis sensitivity, adaptation)



MF, Magnetic Fields: Click to Expand ⟱
Features: Therapy
Magnetic Fields can be Static, or pulsed. The most common therapy is a pulsed magnetic field in the uT or mT range.
The main pathways affected are:
Calcium Signaling: -influence the activity of voltage-gated calcium channels.
Oxidative Stress and Reactive Oxygen Species (ROS) Pathways
Heat Shock Proteins (HSPs) and Cellular Stress Responses
Cell Proliferation and Growth Signaling: MAPK/ERK pathway.
Gene Expression and Epigenetic Modifications: NF-κB
Angiogenesis Pathways: VEGF (improving VEGF for normal cells)
PEMF was found to have a 2-fold increase in drug uptake compared to traditional electrochemotherapy in rat melanoma models

Pathways:
- most reports have ROS production increasing in cancer cells , while decreasing in normal cells.
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx,
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, VEGF↓(mostly regulated up in normal cells),
- cause Cell cycle arrest : TumCCA↑,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓,
- inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, GLUT1↓, LDH↓, HK2↓, PFKs↓, PDKs↓, ECAR↓, OXPHOS↓, GRP78↑, Glucose↓, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, FGF↓, PDGF↓, EGFR↓, Integrins↓,
- Others: PI3K↓, AKT↓, STAT↓, Wnt↓, β-catenin↓, ERK↓, JNK, - SREBP (related to cholesterol).
- Synergies: chemo-sensitization, chemoProtective, cytoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Non-Static Magnetic Fields (AC / Pulsed / Oscillating MF)
Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Reactive oxygen species (ROS) ↑ ROS (P→R); often sustained (G) ↑ ROS (P); ↔/↓ net ROS (R→G) P, R, G Upstream redox perturbation MF perturbs electron/radical dynamics: normal cells often adapt (ROS setpoint ↓), cancer cells less so
2 NRF2 antioxidant response ↔ / insufficient NRF2 induction (R→G) ↑ NRF2 activation (R→G) R, G Adaptive redox defense Explains mixed ROS direction in normal cells (initial ↑ then adaptive ↓)
3 Glutathione (GSH) homeostasis ↓ GSH (R→G) ↔ or transient ↓ (R) with recovery (G) R, G Redox buffering capacity GSH depletion reflects sustained oxidative load; recovery indicates successful adaptation
4 Superoxide dismutase (SOD) / antioxidant enzymes ↔ or inadequate enzyme upshift (G) ↑ SOD/GPx/CAT capacity (G) G Longer-term antioxidant remodeling Often the “endpoint” readout that correlates with ROS-normalization in normal tissue
5 Mitochondrial ETC / respiration ↓ ETC efficiency; ↑ electron leak (P→R) ↔ mild, reversible ETC perturbation (P→R) P, R Bioenergetic destabilization ETC perturbation is a mechanistic bridge between MF exposure and ROS/ΔΨm changes
6 Mitochondrial membrane potential (ΔΨm / MMP) ↓ ΔΨm (R); may progress (G) ↔ preserved or reversible dip (R) R, G Mitochondrial dysfunction thresholding ΔΨm loss typically follows ROS/ETC disruption rather than preceding it
7 Ca²⁺ signaling (VGCC / ER–mitochondria Ca²⁺ flux) ↑ dysregulated Ca²⁺ influx/transfer (P→R); overload may persist (G) ↑ transient Ca²⁺ signaling (P); homeostasis restored (R→G) P, R, G Stress signal amplification Ca²⁺ dysregulation links ROS/ETC perturbation to ER stress and mitochondrial dysfunction (amplifies ΔΨm loss and UPR commitment)
8 Mitochondrial permeability transition pore (MPTP) ↑ MPTP opening propensity (R); sustained opening possible (G) ↔ transient or closed (R→G) P, R, G Commitment point for mitochondrial failure MPTP opening integrates ROS, Ca²⁺ overload, and ΔΨm loss; acts as a threshold event converting reversible stress into irreversible mitochondrial dysfunction
9 ER stress / UPR ↑ ER stress (R); CHOP-commitment possible (G) ↑ adaptive UPR (R); resolves (G) R, G Proteostasis stress Often downstream of ROS + Ca²⁺ handling perturbations
10 DNA damage (oxidative) ↑ damage markers (R→G) ↔ or repaired (G) R, G Checkpoint pressure Generally secondary to ROS; interpret as stress consequence not “direct genotoxicity”
11 LDH / glycolytic flux ↓ glycolytic performance (R→G) ↔ flexible substrate switching (R→G) R, G Metabolic vulnerability Redox imbalance can destabilize high-rate glycolysis in cancer-biased contexts
12 Thioredoxin system (Trx / TrxR) ↓ functional reserve / overload (R→G) ↔ preserved capacity (G) R, G Parallel antioxidant system stress Useful when GSH-only does not explain redox phenotype 
Time-Scale Flag: TSF = P / R / G
  P: 0–30 min (physical / electron / radical effects)
  R: 30 min–3 hr (redox signaling & stress response)
  G: >3 hr (gene-regulatory adaptation)
MPTP: opening represents a mitochondrial commitment event integrating ROS and Ca²⁺ stress; sustained opening indicates irreversible bioenergetic failure.
Scientific Papers found: Click to Expand⟱
1762- MF,  Fe,    Triggering the apoptosis of targeted human renal cancer cells by the vibration of anisotropic magnetic particles attached to the cell membrane
- in-vitro, RCC, NA
Dose∅, Apoptosis↑, Casp↑, tumCV↓, Casp3↑, Casp7↑, Ca+2↑, Cyt‑c↑,
1737- MFrot,  Fe,  MF,    Feature Matching of Microsecond-Pulsed Magnetic Fields Combined with Fe3O4 Particles for Killing A375 Melanoma Cells
- in-vitro, MB, A375
Dose∅, tumCV↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death ⓘ

Apoptosis↑, 1,   Casp↑, 1,   Casp3↑, 1,   Casp7↑, 1,   Cyt‑c↑, 1,  

Transcription & Epigenetics ⓘ

tumCV↓, 2,  

Migration ⓘ

Ca+2↑, 1,  

Drug Metabolism & Resistance ⓘ

Dose∅, 2,  
Total Targets: 8

Pathway results for Effect on Normal Cells:


Total Targets: 0

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:104  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page